All In Biotech

Drug Trial Radar · NCT07079579

Enarodustat Tablets at Different Initial Doses for Anemia in Non-dialysis CKD Patients

A Prospective, Single-arm, Open-label Study to Evaluate Different Initial Doses of Enarodustat Tablets for the Treatment of Anemia in Patients With Non-dialysis Chronic Kidney Disease

Last checked: Nov 20, 2026Latest source record: Jul 23, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 120 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Aug 2025

Primary completion

Jun 2027

Study completion Dec 2027

Sponsor

Sponsor type
Industry
First posted
Jul 23, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To evaluate the rationality of different initial doses of enarodustat for the treatment of anemia in ND-CKD patients

Conditions

  • Renal Anemia in Non-dialysis Chronic Kidney Disease

Interventions

  • Enarodustat 2mgDrug

    initial phase:2mg QD for 4 weeks subsequent phase:1mg、2mg、4mg、6mg、8mg QD,adjust the dose based on hemoglobin concentration level every 4 weeks

  • Enarodustat 3mgDrug

    initial phase:3mg QD for 4 weeks subsequent phase:1mg、2mg、4mg、6mg、8mg QD,adjust the dose based on hemoglobin concentration level every 4 weeks

  • Enarodustat 4mgDrug

    initial phase:4mg QD for 4 weeks subsequent phase:1mg、2mg、4mg、6mg、8mg QD,adjust the dose based on hemoglobin concentration level every 4 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Mean Hb level at Week 16 of treatmentTime frame: week 16

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Chinese PLA General Hosptial

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.